On June 6, 2025, Sutro Biopharma held its Annual Meeting where shareholders elected three directors, approved the appointment of Ernst & Young as accountants, and voted on a reverse stock split between 1-for-5 and 1-for-25. The proposal for executive compensation was also approved.